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Worldwide, COPD is a leading cause of chronic morbidity and mortality. Although its preva-
lence is already well documented, very few studies have measured its incidence. We therefore
investigated the prevalence, incidence and lifetime risk of COPD in the general population.
In a population-based study including subjects  40, with 12 months of history available in
the Dutch IPCI database, we identified COPD cases by a two-step validation algorithm.
Among 185,325 participants with 601,283 years of follow-up, 7308 subjects with COPD were
identified, and 1713 had incident COPD. The overall IR of physician-diagnosed COPD was 2.92/
1000PY (95%CI 2.78e3.06). The incidence of COPD was higher in men (3.54; 95%CI 3.33e3.77)
than in women (2.34; 95%CI 2.17e2.52), and the overall baseline prevalence of COPD was
3.02% (95%CI 2.94e3.10). For people who had entered the study free of COPD at the age of
40, the risk of developing COPD within the next 40 years was 12.7% for men and 8.3% for
women. In patients with very severe COPD, 26% died after 1 year of follow-up, whereas
2.8% died among the non-COPD subjects.
In the general population in theNetherlands, three on 1000 subjectswere diagnosedwith COPD
per year. The incidence increased rapidly with age and was higher in men than in women. One inpeutic chemical; CI, confidence interval; COPD, chronic obstructive pulmonary disease; GOLD, global
disease; GPs, general practitioner(s); ICPC, international classification of primary care; IPCI, inte-
incidence rate; PY, person-years; RR, relative risk; SD, standard deviation; WHO, world health
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COPD in the general population 1873eight men and one in 12 women, being COPD free at the age of 40, will develop COPD during their
further life. Mortality rates differed substantially between COPD patients and non-COPD subjects
of the same age, underlining the burden of this disease.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is charac-
terized by a largely irreversible obstruction of the airways,
and encompasses both emphysema and chronic bronchitis.1
The obstruction of the airways is usually progressive, and
often associated with an abnormal inflammatory response
of the lungs to harmful particles or gases such as tobacco
smoke. COPD is a leading and still-increasing cause of
chronic morbidity and mortality worldwide,2 and according
to the World Health Organization (WHO), it is the fifth most
common cause of death and the 10th most burdensome
disease.3 Chapman et al.4 and Mannino et al.5 projected
that between 1990 and 2020, COPD will become the third
most common cause of death worldwide. A Dutch study
predicts that an increase of 76% in the prevalence of COPD
can be expected within approximately twenty years.6
Although the prevalence of COPD has been well stud-
ied,7e11 there are less population-based studies11e19 which
have investigated its incidence. Among the studies that have
been conducted, a wide range in incidence rates can be
observed varying between 2e16/1000PY depending on the
COPD definition being used and the population being stud-
ied.11e14,16e21 Little is known about trends in COPD preva-
lence, incidence and all-cause mortality.20
COPD is one of the few chronic diseases that caused an
increase in mortality in recent years.22 In 1990, the WHO
estimated the European standardized mortality rate of
COPD to be 50 per 100,000 in males and 20 per 100,000 in
females.23,24 Data provided by the WHO in 1997, showed
that COPD was the cause of death in 4.7% of men and 2.4%
of women23,24 in Europe, and the World Health Report of
1998 stated that 2.9 million adults die each year of this
disease.24,25 Death rates in patients with COPD are usually
lower among women than among men in all countries. At
present, there are few observational studies reporting
mortality rates in COPD patients.20,25e28
The objectives of our study were to investigate the
prevalence, incidence, mortality and lifetime risk of COPD
as a function of age, sex and smoking status in the general
population.MethodsSetting
The study was conducted within the Integrated Primary
Care Information (IPCI) database, a longitudinal observa-
tional database (dynamic cohort), that started in 1992 and
contains data from computer based medical records of
general practitioners (GPs) throughout the Netherlands.29
The database covers data from more than 400 GPs who
currently capture data on more than 1 million patients.29 In
the Dutch health care system, patients are registered witha single GP who acts as a gatekeeper for and receiver of
information from secondary care.30 The GPs’ electronic
medical records contain coded and anonymous data on
patient demographics, narratives, patient reported symp-
toms, signs, GP and specialist diagnoses (using the Inter-
national Classification of Primary Care (ICPC) codes and
free-text31), as well as prescriptions, physical findings,
laboratory values, and summaries of specialist letters.29,31
Downloads are made periodically and the information is
sent to the gatekeeper who de-identifies all information
before further access is provided.
Prescription data encompass product name, quantity
dispensed, dosage regimens, strength and indication. The
National Database of drugs, maintained by the Royal Dutch
Association for the advancement of Pharmacy, enables the
coding of prescriptions, according to the Anatomical Ther-
apeutic Chemical (ATC) classification scheme recommended
by the WHO.32e34 The system complies with European Union
guidelines on the use of medical research and has been
proven valid for pharmaco-epidemiological research.34 All
observational research using IPCI data is conducted
according to good pharmaco-epidemiological guidelines.35
Source population
The source population comprised 185,325 men and women
aged 40 or older, with at least one-year of valid database
history meaning that the practice had been contributing data
to the IPCI database for at least one-year and that the patient
had been registered with the GP for at least one-year. This
one-year pre-enrollment period was required to guarantee
sufficient medical history prior to study entry. The study
started on 1 January 2000 or the date at which one-year of
valid history was obtained. All patients were followed from
study entry until the date of diagnosis of (incident) COPD,
death or 1 July 2007, whichever occurred first.
COPD cohort
A broad automated search was conducted on ICPC COPD
disease codes and narratives to identify all potential COPD
patients. The medical records of all potential cases were
reviewed by a medical doctor and classified as: definite
COPD e diagnosis by a specialist or a GP diagnosis confirmed
by spirometry (GOLD definition of FEV1/FVC<70%); prob-
able COPD e COPD diagnosed by the GP with at least two
records of COPD within one-year of the first record of
COPD. Doubtful COPD patients were further reviewed and
classified by a pulmonologist (GB).
All COPD patientswere further categorized into prevalent
or incident COPD. Patients with a COPD diagnosis prior to
study entry were classified as prevalent (pre-existing) COPD.
If patients were disease free (no COPD specific respiratory
symptoms, no COPD disease codes, no respiratory treatment
for COPD, and no specialist letters referring to a diagnosis of
1874 A.S.M. Afonso et al.COPD) at cohort entry and later developed COPD, they were
considered as having incident (new onset) COPD.
COPD severity was assessed at the time of cohort entry
and changes in COPD severity were captured during follow-
up. If spirometry data were available, severity of COPD was
assessed according to the GOLD criteria. In all other
patients, previously published algorithms for COPD severity
assessment were used.36e38 For further details on COPD
severity assessment, see online supplement.
Statistical analysis
The baseline characteristics of the COPD cohort were
compared to the baseline characteristics of the population
via the ManneWhitney U test for continuous variables, and
the Chi-square test for categorical variables. Age and
gender-specific incidence rates of COPD (IRs) per 1000
person-years (PY) and cumulative prevalence of COPD, all
stratified by smoking status, as well as weighted (3 year
mean) annual incidence rates were calculated (See online
supplement). A direct and indirect standardization
method was used to compare the incidence rate to the
COPD incidence rate of a reference population.
Thecumulative incidenceand the lifetimeriskofCOPDwas
calculated on the basis of a Cox regressionmodel adjusted for
competing risk of death, as described by Rosthoj et al.39
Crude and adjusted hazard ratios of incident COPD were
calculated using a Cox regression analysis. In the final
model, we adjusted for all factors that, in the univariate
analysis, were associated with the outcome.
To compare the mortality rates in subjects with or
without COPD, to each COPD patient, 4 controls were
sampled from the source population, matched on age, sex,
smoking status and calendar year (year of entry into the
cohort). Mortality rates were calculated by dividing the
number of deaths by the person years attributed. Survival
analyses were conducted using KaplaneMeier analysis.40 All
statistical analyses were conducted with SPSS/PC 15.0
(SPSS Inc., Chicago, Ill), SAS and Episheet (by Rothman).
Results
Baseline characteristics
In the source population of 185,325 patients with at least
one-year of valid history (601,283 years of follow-up time),
18,643 COPDpotential caseswere identified (Fig. E1e online
supplement). The mean follow-up time was 3.4 years (stan-
dard deviation (SD),3.2 years). After manual review of the
complete medical record, 7308 patients were identified as
having COPD of which 57% were male. Table 1 shows the
baseline characteristics of the total source population at
study entry (n Z 185,325) and the patients with COPD
(nZ 7308), both incident and prevalent. COPDpatientswere
older, more frequently male, and had more co-morbidity
than non-COPD patients at study entry (Table 1).
A total of 5595 patients (77%) in the COPD cohort had
prevalent COPD at baseline and 1713 (23%) were incident
COPD patients. Incident COPD patients were slightly
younger than the prevalent ones (mean age 64.7,
SD  11.8, versus 67.8, SD  12.3), and more often smokedor had smoked in the past (Table 1). The mean and median
age at first diagnosis did not change over time (data not
shown). The majority of incident COPD patients had mild
COPD at the time of first diagnosis.
Co-morbidity was similar between incident and preva-
lent COPD patients apart from a history of heart failure,
which was more often recorded in prevalent COPD patients
(12.4% versus 10.4%), and myocardial infarction, hyper-
tension, lipid disorders and a history of depressive disor-
ders, which were more common in incident COPD patients
(Table E1 e online supplement).
Risk factors of incident COPD
Table 2 describes the risk factors of incident COPD. Male
gender, increasing age and smoking history were strong risk
factors of COPD and these associations remained significant
after adjustment. Cardiovascular co-morbidity was strongly
related to the risk of incident COPD in the crude analysis,
but these associations weakened upon adjustment. A
medical history of asthma and pneumonia in the one-year
prior to study start were strongly associated with incident
COPD (Table E2 e online supplement).
Incidence, prevalence, risk and mortality
The overall incidence of COPD in persons 40 years and older
was 2.92/1000PY (95%CI, 2.78e3.06) (Table E3a e online
supplement). The incidence of COPD was higher in men
than in women (with a relative risk (RR) of 1.5-fold higher in
men). The incidence increased almost 10-fold from 0.78/
1000PY at age 40e44 to 6.82/1000PY at age 75e79 (Fig. 1).
The incidence rate of COPD was much higher in smokers
compared to non-smokers and this for all age categories
and in both sexes (Fig. 2) (Table E3 b e online supplement).
The prevalence of COPD at cohort entry was 3.02%, 95%
CI (2.94e3.10). The age-specific cumulative prevalence of
COPD increased with age until the age of 81 years in men
and 83 years in women. After this age, the prevalence did
no longer increase and even gradually declined, especially
in men. The prevalence of COPD was, for all age categories,
higher in men than in women (Fig. E2 e online supplement)
and higher in ever-smokers than in non-smokers (Fig. E3 e
online supplement).
For a man free of COPD at the age of 40, the risk to be
diagnosed with COPD was 0.8% (10 years), 2.8% (20 years),
7.2% (30 years) and 12.7% (40 years) respectively. For
a woman of the same age, the risks were 0.8%, 2.3%, 5.0%
and 8.3% (Fig. 3). Here as well, the cumulative incidence of
COPD was much higher in ever-smokers than in non-
smokers, both for men and women (Fig. 4).
Mortality rates were 2.0-fold higher for COPD patients
than for the age and sex matched reference population.
Mortality rates increased with COPD severity from 48.1/
1000PY (95%CI, 42.5e54.3/1000PY) in mild to 262/1000PY
(95%CI, 179e371/1000PY) in very severe COPD patients
(Table 3). Survival is lower in COPD patients than non-COPD
subjects and is highly influenced by COPD severity (Fig. 5).
The one-year risk of dying was 26% (95%CI 18.4e35.4%) in
the very severe COPD patients, while the risk in the sex and
age matched reference group was nearly ten times lower
namely 2.8% (95%CI 0.92e8.17%).
Table 1 Patient characteristics of source population and COPD cohort.
Characteristics Source population n Z 185,325 Overall COPD Incident COPD Prevalent COPD
No. % No. % No. % No. %
Number of COPD patients 7308 3.9 7308 100.0 1713 23.4 5595 76.6
Gender
Males 89,697 48.4 4153 57.3 995 58.1 3158 56.4
Females 95,628 51.6 3155 42.7 718 41.9 2437 43.6
Age (years)
40e59 119,798 64.6 1982 26.5 501 29.2 1481 26.5
60e69 30,930 16.7 1872 25.6 473 27.6 1399 25.0
70 34,597 18.7 3454 47.9 739 43.1 2715 48.5
Mean age (SD) 56.5 13.3 67.8 12.1 64.7 11.8 67.8 12.3
Ever smokinga 39,250 21.2 3468 47.4 1028 60.0 2440 43.6
Smoking historya
Never smoker 506 6.9 130 7.6 376 6.7
Current smoker 3009 41.2 854 49.9 2155 38.5
Past smoker 459 6.3 174 10.2 285 5.1
Smoking not specified 3334 45.6 555 32.4 2779 49.7
Severity at cohort entrya
Severity by spirometry
Mild (GOLD stage I) 639 9.0 243 14.2 393 7.0
Moderate (GOLD stage II) 923 13.3 187 10.9 736 13.2
Severe (GOLD stage III) 558 8.1 73 4.3 485 8.7
Very Severe (GOLD stage IV) 21 0.3 3 0.2 18 0.3
Severity by proxy
Mild 2352 30.7 1115 65.1 1237 22.1
Moderate 1968 26.7 40 2.3 1928 34.5
Severe 768 10.8 50 2.9 718 12.8
Very Severe 81 1.2 1 0.1 80 1.4
Mean time since first diagnosis (years) (SD) 0 0 3.16 4.47
a At baseline for prevalent COPD patients or at the date of diagnosis for incident COPD patients.
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In this large population-based cohort study of the general
Dutch population of 40 years and older, the overall inci-
dence rate of physician-diagnosed COPD was 2.92/1000PY.
Based on these data the risk to be diagnosed with COPD inTable 2 Risk factors of incident COPD.
Patients/Cohort No. HRcrude
COPD risk factors
Gender
Female 718/92,473 Reference
Male 995/85,544 1.51
Age at baseline
40e59 592/117,825 Reference
60e69 506/29,061 3.47
70 615/31,131 6.64
Smoking status
Never smoker 685/142,235 Reference
Ever smoker 1028/35,782 3.67
Patients with prevalent COPD (n Z 5595) excluded from this analysis
a Adjusted for all factors that were univariately associated with th
underlying co-morbidity (history of stroke/TIA, myocardial infarction
disease, diabetes mellitus, renal failure, pneumonia (previous year),the coming 40 years was 12.7% for a 40-year-old male and
8.3% for a 40-year-old female. The incidence increased with
age, and was higher in men than in women. Known risk
factors of COPD were confirmed such as smoking status,
male gender and increasing age. Mortality was high; espe-
cially in very severe COPD patients with one-year mortality95%CI HRadjusted
a 95%CI
Reference Reference Reference
1.37e1.67 1.65 1.49e1.82
Reference Reference Reference
3.06e3.94 3.67 3.23e4.17
5.93e7.44 8.55 7.58e9.65
Reference Reference Reference
3.33e4.04 3.89 3.52e4.31
.
e outcome namely gender, smoking status, age at baseline and
, heart failure, hypertension, angina pectoris, peripheral artery
asthma, depression and hyperlipidemia).
1876 A.S.M. Afonso et al.risks nearly 10-fold that of non-COPD subjects of the same
age and gender.
Previous studies mainly focused on the prevalence of
COPD as they often applied a cross sectional spirometry
based approach to obtain the true prevalence of COPD. Few
spirometry based incidence studies have been
reported.11e14,16,17,19 (Table 4) Studies reporting diagnosed
COPD, based on health care databases, were conducted in
the UK and in Canada (Table 4).18,20,21 The most recent
incidence study, published in 2010, is a Canadian study
investigating trends in incidence, prevalence and mortality
of COPD over time.20 For this study, the Ontario Health
Insurance Plan database was used and COPD was defined
based on visits and hospitalization with ICD-9 or ICD-10 codes
for COPD.20 The incidence of COPD was high: 11.8/1000 in
1996 and 8.5/1000 in 2007.20 The rates of incidence and
prevalence were much higher than observed in our study
(even after standardization), but the study was very inclu-
sive and COPDwas not validated. COPDCodes included terms
such as chronic bronchitis and asthmatic bronchitis which
not necessarily are synonyms of COPD.20 Our COPD definition
was much stricter, requiring specialist diagnosed COPD orFigure 1 Age- and gender-specific incidence rates of physician-
calendar year-specific incidence of COPD (bottom).COPD diagnosed by GPwith spirometry data and/or at least 2
records of COPD within one-year, explaining our lower IRs.
van Durme et al. also studied the incidence of COPD in
a prospective cohort of elderly in the Netherlands. COPD
was defined based on specialists/GPs (similar to ours)
diagnosis as well as on tri-annual spirometry assessments.
Our age standardized rate was 35% lower showing the level
of under-diagnosis.11 Using the indirect age standardiza-
tion, the calculated standardized incidence rate was 0.49
(95%CI 0.46e0.52). We thus identified only half of the COPD
patients as expected based on the incidence rate of the
Rotterdam study. Our IR is much lower than in the study
from van Durme et al., as in the latter, spirometry was
conducted on 44% of the study population, whereas in our
setting, spirometry was only performed if the subject
seeked medical attention because of respiratory
complaints. Our IRs are more in line with the results of
a recent population-based cohort study, using primary care
data (UK GPRD database) as well and similar method-
ology.18 The incidence rate of physician-diagnosed COPD in
40e89 year-olds was 2.6/1000PY, which is almost identical
to the incidence rate we found (2.9/1000PY).18diagnosed COPD (/1000PY) (top) and weighted (3 year mean)
COPD in the general population 1877These differences in COPD incidence rate can be
explained by differences in COPD definition and/or by
under-diagnosis (the use of spirometry as a diagnostic test
in symptomatic subjects seeking medical attention versus
the use of spirometry as screening tool for the detection of
COPD). In addition, we applied a very strict COPD validation
algorithm, indeed, of all potential cases with COPD, only
39% were withheld as having COPD. Since respiratory
symptoms are often absent in patients with COPD and since
not all patients with respiratory symptoms seek medical
attention, the incidence of physician-diagnosed COPD (this
study) is lower than the incidence of spirometry defined
COPD.11,41
After the age of 81 years in men and 83 years in women,
the COPD prevalence did no longer increase and even
gradually declined. Although the exact mechanism is
unknown, this could be explained by the “healthy survivor
effect”, where patients with COPD die before the age of 80.Figure 2 Age- and gender-specific incidence rates of physician-
calendar year-specific incidence of COPD (bottom) by smoking.In our study, all-cause mortality rates were higher in
COPD patients than in patients without COPD of similar age
and sex. Our mortality rates are much in line with the data
from Soriano et al.25 and Gershon et al.,20 who also studied
mortality in COPD patients. In their study, Gershon et al.
describe mortality rates that vary between 5.7% in 1996 and
4.3% in 2007,20 which is in line with the mortality rate of
6.1% that we found in our COPD patients. Soriano et al.
reported an overall death rate of 8.5% per year.25
Furthermore, in comparison with data of patients with
COPD followed by GPs,42 Lundback et al. refer to a better
survival among the subjects with COPD identified by an
epidemiological population study, with a 5-year risk of
dying of approximately 7% in subjects without both chronic
bronchitis and asthma-like phenotype, and approximately
15% in subjects with chronic bronchitis.43 Our 5-year risk of
dying was somehow higher with 14% in non-COPD patients
and 27% in COPD patients, probably because Lundbackdiagnosed COPD (/1000PY) (top) and weighted (3 year mean)
Figure 3 Age-related risk to develop COPD over the coming 10, 20, 30, and 40 years in men (top) and women (bottom).
CI Z cumulative.
1878 A.S.M. Afonso et al.et al. included younger patients, applied another COPD
definition and used different in and exclusion criteria.
Similar to previous literatures,20,25e28 we found that
mortality in patients with COPD is higher in men than in
women. A partial explanation could be that, on average,
women with COPD still have less severe COPD or smoke less
than men.
As for all observational studies, our study has strengths
and weaknesses. The strength of this study is the
population-based design; its large cohort size and the
detailed information on underlying co-morbidity. Further-
more, the large population in this study is representative of
the general population, which eliminates selection bias. To
avoid inclusion of false positive cases we followed
a rigorous validation algorithm and used data from
spirometry and specialist referral letters, if available. In
addition, we assessed COPD severity according to spirom-
etry data or according to an algorithm already successfullyused by other research groups.36e38 As this is a population-
based study, we did not have spirometry data on all
subjects. For this reason we believe that we probably
underestimated the true incidence rate of COPD in the
general population, resulting in an under-diagnosis of COPD
due to lack of spirometry performed and/or recorded. This
is one of the reasons why our COPD incidence rate is lower
than in those studies where COPD was systematically
assessed by spirometry. In our study, patients diagnosed to
have COPD are mainly the ones presenting themselves with
respiratory symptoms. Some patients with COPD never
develop respiratory symptoms and a considerable propor-
tion of patients with respiratory symptoms get accustomed
to these complaints and never consult their GP.41,44
Among patients with spirometry data, we used the GOLD
definition of COPD (FEV1/FVC < 70%) instead of the use of
LLN values for FEV1/FVC. It is known that the FEV1/FVC
ratio declines with age, and thus the true lower limit of
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Figure 4 Age-related risk to develop COPD over the coming 10, 20, 30, and 40 years in men (1 and 2) and women (3 an 4) by
smoking status. CI Z cumulative.
Table 3 Number of deaths and mortality rates (/1000PY) in patients with and without COPD.
COPD Non-COPDa
All Mild Moderate Severe Very severe
Total number
patients, n (%)
7308 2989 (40.9) 2891 (39.6) 1326 (18.1) 102 (1.4) 24,722
Number of deaths 1371 393 523 402 53 2750
Males 897 (65.4) 259 (65.9) 329 (62.9) 280 (69.6) 29 (54.7) 1886 (68.6)
Females 474 (34.6) 134 (34.1) 194 (37.1) 122 (30.3) 24 (45.3) 864 (31.4)
Mean (SD) age
at death
78.2 (9.3) 78.2 (9.8) 78.9 (8.8) 77.7 (9.2) 73.6 (9.7) 79.7 (8.6)
Age at death,
n (%)
40e59 53 (3.9) 18 (4.6) 15 (2.9) 15 (3.7) 5 (9.5) 89 (3.3)
60e69 195 (14.2) 54 (13.7) 64 (12.2) 64 (16.0) 13 (24.5) 261 (9.5)
70 1123 (81.9) 321 (81.7) 444 (84.9) 323 (80.3) 35 (66.0) 2400 (98.2)
Mortality rate
(/1000PY),
95%CI
_ 70.4
(65.9e75.1)
48.1
(42.5e54.3)
63.9
(57.3e71.1)
133.4
(118.5e149.8)
262.0
(179.1e370.9)
36.3
(34.7e38.0)
\ 48.5
(44.3e53.0)
33.5
(28.2e39.6)
47.5
(41.1e54.5)
76.8
(64.0e91.3)
236.7
(195.5e404.9)
21.7
(20.3e23.2)
All 60.9
(57.7e64.2)
41.9
(37.9e46.2)
56.6
(51.9e61.6)
109.0
(98.7e120.1)
249.9
(189.2e324.2)
30.0
(28.9e31.1)
a Matched for age, sex, smoking status and calendar year (year of entry in the cohort); 4 controls were sampled from the source
population for each COPD patient.
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1880 A.S.M. Afonso et al.normal (LLN) for FEV1/FVC also declines. This may result in
misclassification of disease, with an over-diagnosis in the
elderly and under-diagnosis in the young age categories.45
The sex differences in incidence rates may also be influ-
enced by this reasoning since the cross over point for a plot
of the fixed ratio FEV1/FVC and the true LLN against age is
at a later age in women.46 We are aware of this limitation,
but as information on height and race is not systematically
reported in the database, we were not able to calculate the
LLN and had to use the fixed ratio of FEV1/FVC instead.
47Figure 5 Survival among (top) men and (bottom) women diagn
(controls are COPD free).Finally, in all observational research, misclassification of
death and cause of death could be a concern although very
unlikely in the context of the IPCI database. First, we
retrieved all patients identified as being deceased from the
demography file in the IPCI database. In addition, we con-
ducted a free-text search on “death” and reviewed the
complete medical record (including discharge letters). The
cause of death, as adjudicated by the IPCI researchers, was
further verified with the GP in an initial sample of 10% of all
respiratory or cardiovascular related deaths. The positiveosed with COPD by severity status and reference population
Table 4 Overview of studies that investigated the incidence of COPD.
Author Source population Country COPD
definitiona
Year of
study
Cohort
size
Follow-up
time
Number of
incident
COPD
patientsb
Age
range in
years
IR COPDb
Spirometry based studies
van Durme et al.11
Chest 2009
Population based the Netherlands
(Rotterdam)
Spirometry/
discharge
letters
1990e2004 7983 11 yrs 648 55 9.2/1000PY
Krzyzanowski M et al.12
Am R Res Dis 1986
Longitudinal data,
random sample; older
persons and those with
chest complaints
performed lung function
tests
Poland (Cracow) Spirometry 1968e1981 4612 13 yrs 1864 19e70 5.0/1000PY
Huhti E et al.13
Eur J Res Dis 1980
Non-selected population
and standard
questionnaire on
respiratory symptoms
completed for each
subject
Finland
(Harjavalta)
Spirometry 1961e1971 1476 10 yrs 1163 40e64 2.0/1000PY and
10.0/1000PY for
smokers
de Marco R et al.17
AJRCCM 2007
ECRHS on random sample
of young adults.
Participants were invited
by questionnaire. Of the
responders, a random
sample of 20% were
invited for spirometry
Belgium,
Denmark, Estonia,
France, Germany,
Iceland, Italy, the
Netherlands,
Norway, Spain,
Sweden,
Switzerland, UK
Spirometry
(FEV1/
FVC < 70%)
ECRHS I:
1991e1993
ECRHS II:
1999e2002
5002 8.9 yrs 123 20e44 2.8/1000PY
10 yrs CI 2.8%
Lindberg A et al.16
Chest 2006
Participants selected via
postal questionnaire and
a random sample was
invited to a structured
interview and spirometry
in 1996 and 2003
Sweden
(Noorbotten)
Spirometry
(GOLD)
85% (1009)
participated in
1996 and 2003
963 7 yrs 45 (Gold II
and more)
91 (Gold I
and more)
46e77 6.7/1000PY Gold II
(CI 4.9%)
13.5/1000PY Gold
I and more (CI
11.0%)
Vestbo J et al.14 General population
sample without COPD at
study entry, selected at
random after age
stratification.
Denmark
(Copenhagen)
Spirometry 1976e1778
1981e1983
1992e1994
14,223
(maximal)
9 yrs Not
mentioned
20
years
19/1000PY (5 yrs)
and 9/1000PY
(15 yrs)
5 yrs CI 9.7% and
15 yrs CI 13.2%
(continued on next page)
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Table 4 (continued)
Author Source population Country
COPD
definitiona
Year of
study
Cohort
size
Follow-up
time
Number of
incident
COPD
patientsb
Age
range in
years IR COPDb
Johannessen A
et al.19
Participants selected
via postal questionnaire
(1985), a questionnaire
(1987e8) and spirometry
(1996e7)
Norway
(Bergen)
Spirometry
(GOLD
criteria)
1985, 1987e8
(84% e1275
p.), 1996e7
(1123 p.)
908 12 yrs 40 18e74 7/1000PY (annual
incidence)
6.1% (9-year CI)
Diagnosis based studies
Garcia Rodriguez
et al.18
Population based-GPRD UK Based on COPD
specific OXMIS
and Read Codes
1996 808,513 Not
specified
1927 40e89 2.6/1000PY
Huerta C et al.21 Population based-GPRD UK Presence of
recorded
diagnosis
of COPD
1993e1998 5000 6 yrs 206 60e85 7.2/1000PY
Gershon et al.20 Population based-Claims
database
Canada ICD codes 1996e2007 5e6.4
million
12 yrs 61,998e
55,903
35 11.8e8.5/1000PY
Abbreviations: CIZ Cumulative incidence, ECRHSZ European community respiratory health survey OXMISZ Oxford medical information system, READ codesZ current UK coding system
for diseases.
a BTS criteria: FEV1/FVC ratio, <0.70; and FEV1, <80% predicted; GOLD criteria: FEV1/FVC ratio, <0.70.
b GOLD: GOLD stage I to IV with FEV1/FVC ratio of <0.70; GOLD II: GOLD II and higher with FEV1/FVC ratio if <0.70 and FEV1<80%
predicted.
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Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.rmed.2011.
06.012.
COPD in the general population 1883predictive value was high, as cause of death was confirmed
in more than 90%.
In conclusion, in the Netherlands around 3 on 1000
subjects are newly diagnosed with COPD per year; however,
the true incidence of COPD, based on spirometry criteria,
may be 30e40% higher. The lifetime risk that COPD would
be diagnosed over the coming 40 years, if diagnostic
criteria and processes remain the same, is 12.7% for a 40-
year-old-man still free of COPD and 8.3% for a woman. If
ascertainment increases this is likely to be higher. Mortality
rates are substantially higher in patients with COPD than in
the general population, which emphasizes the need for
better primary and secondary prevention in patients with
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